Els O. Witteveen

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell et al. · Clinical Cancer Research · 2007 · 176 citations

Medicine, Oncology, Pharmacology +16

Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

Tessa M. Bosch, Alwin D. R. Huitema, Valerie D. Doodeman et al. · Clinical Cancer Research · 2006 · 125 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study

Kristel Van Calsteren, René Verbesselt, Nelleke Ottevanger et al. · Acta Obstetricia Et Gynecologica Scandinavica · 2010 · 123 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors

Laurens V. Beerepoot, Sandra A. Radema, Els O. Witteveen et al. · Journal of Clinical Oncology · 2006 · 114 citations

Medicine, Oncology, Pharmacology +13

Late Release of Circulating Endothelial Cells and Endothelial Progenitor Cells after Chemotherapy Predicts Response and Survival in Cancer Patients

Jeanine M.L. Roodhart, Marlies H.G. Langenberg, Joost S.P. Vermaat et al. · Neoplasia · 2010 · 79 citations · Full text

Medicine, Oncology, Pharmacology +9